Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

tock issuable upon conversion of the notes, nor shall there be any offer, solicitation or sale of any securities, including any notes or any shares of the Company's common stock issuable upon conversion of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"), which include, among other things, those concerning whether or not the Company will offer the notes or consummate the proposed offering, the final terms of the notes and the proposed offering, prevailing market conditions, the anticipated principal amount of the notes and the anticipated use of the proceeds of the proposed offering.  The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Act.  Forward-looking statements may be ident
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Currently offering a comprehensive portfolio ... Weighing, Rice Lake, and Ohaus, Pipette.com has added ... Sartorius CPA Semi-Micro Balance is ideal for lab ... user-friendly laboratory balance. , Sartorius is a global ... balances are well known for their high performance, ...
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... 2014 Mapp Biopharmaceutical,s valiant effort to ... to fight the Ebola outbreak will make the ... production of pharmaceuticals can be, according to Kalorama ... while some may be taken aback by the ... industry knowledge are well aware of the complex ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2
... March 16 Micromet, Inc. (Nasdaq: MITI ), ... of cancer, inflammation and autoimmune diseases, today announced the publication ... meeting of AACR taking place from April 20-24, 2009, in ... , Lutterbuese, ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) ... of innovative therapeutic products for the treatment of cancer, ... a notice from the NASDAQ Hearings Panel that Oncothyreon ... of The NASDAQ Global Market. , The notice followed ...
... take two bricks and place them side by side a ... the bricks will be covered with snow and barely discernible. ... around the bricks. , What you will see, says Ivan ... smallest of scales on an integrated optical circuit, could hasten ...
Cached Biology Technology:Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 2Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 3Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 4Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research 5Oncothyreon regains compliance with NASDAQ listing requirements 2New organic material may speed Internet access 2New organic material may speed Internet access 3New organic material may speed Internet access 4New organic material may speed Internet access 5
(Date:10/15/2014)... have linked increased resistance to bacterial pneumonia in female ... hormone estrogen. , Females are naturally more resistant to ... scientists has shown that increased resistance to bacterial pneumonia ... oxide synthase 3 (NOS3). They also show that this ... female sex hormone estrogen. , The team, lead by ...
(Date:10/15/2014)... be awarded the 44th Rosenstiel Award for Distinguished Work ... research exploring the mechanisms of genomic instability and its ... is the second alumnus to win the Rosenstiel Award; ... 2003. , Alt is the Charles A. Janeway Professor ... School and an investigator at the Howard Hughes Medical ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Prostate cancer's penchant for copper may be a fatal flaw 2
... MANHATTAN, KAN. -- New findings about the causes of ... genetic. "We now know it,s also in the ... Professor of Diagnostic Medicine and Pathobiology at Kansas State ... ago, Richt said, it was thought that the cattle ...
... Neurons constituting the optic nerve wire up to the ... developing retina sprout processes, called axons, which extend toward visual ... U-turns when they take the wrong path. How they find ... Using the mouse visual system, a team of Salk ...
... CITY After years of working toward this goal, scientists ... isolate cancer stem cells in tumors so they can target ... A research team at the University of Oklahoma led ... a particular protein only appears in stem cells. Until now, ...
Cached Biology News:K-State professor's USDA research shows mad cow disease also caused by genetic mutation 2A second career for a growth factor receptor: keeping nerve axons on target 2A second career for a growth factor receptor: keeping nerve axons on target 3
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
p-Raf-1 (Ser 338/Tyr 341)-R...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: